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Abstract
Despite the discovery in the last decade of azoles and echinocandins as novel and potent antimycotic drugs, systemic Candida infections
are still accompanied by an unacceptably high burden of morbidity and mortality. A rational novel therapeutic approach would be the
use of adjuvant immunotherapy, with the aim of improving host defence against Candida. Increases in our understanding of the mecha-
nisms that underlie the pathogenesis of Candida infections, such as the role played by pattern recognition receptors and the induction
of proinﬂammatory cytokines during the early phases of infection, have led to the hypothesis of a potential therapeutic role of recombi-
nant cytokines in systemic candidiasis. In the present review, we give an update of both experimental data and proof-of-principle studies
in humans that argue for the use of adjunctive immunotherapy with recombinant cytokines in invasive Candida infections. Sufﬁciently
powered studies on the role of cytokine-based treatment regimens for invasive candidiasis are needed to fully demonstrate the feasibil-
ity of this immunotherapeutic approach to improve the prognosis of severe invasive Candida infections.
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Introduction
Systemic fungal infections, particularly those caused by Can-
dida species, have become a leading cause of morbidity and
mortality. This is especially true for severely ill patients, both
immunocompetent and immunocompromised, who have an
increased risk of nosocomial Candida infection [1–4]. The
pathogenicity of opportunistic Candida infections is largely
related to inadequate host defences, rather than to an intrin-
sic virulence of the fungus. Important risk factors for Candida
infections include the use of broad-spectrum antibiotics, the
presence of central venous catheters, total parenteral nutri-
tion, abdominal surgery, previous colonization with Candida
species, and low neutrophil count [1,5–7]. Despite improve-
ments in antifungal therapy with the discovery of azoles and
echinocandins, mortality in patients with candidiasis remains
very high, being reported between 30% and 50% [1–3,5,6].
Therefore, new therapeutic approaches are urgently needed
to improve the outcome of patients with disseminated candi-
diasis. We have recently proposed that the use of immuno-
therapy, which aims at improving host defence against
Candida, could provide a solution to reduce the high mortal-
ity rate in invasive candidiasis [8]. In the present review, we
give an updated overview of the mechanisms that underlie
the pathogenesis of Candida infection that provide the ratio-
nale for the use of adjuvant immunotherapy, with a focus on
the use of recombinant cytokines as a strategy to improve
antifungal host defence.
Host Defence Mechanisms in Disseminated
Candidiasis
Pattern recognition of Candida species
The ﬁrst step in the innate host defence during a systemic
infection in general, and an infection with Candida species in
particular, is triggered by the recognition of fungal cell wall
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components by pattern recognition receptors (PRRs) on the
surface of cells of the innate immune system [9,10]. In the
last decade, much has been learned about the classes of PRR
that are capable of recognizing Candida albicans [11–13],
which is still the most common species of Candida diagnosed
in fungal sepsis. Three of the four major families of PRR have
been implicated in recognition of C. albicans: the Toll-like
receptors (TLRs), the C-type lectin receptors (CLRs), and
the nucleotide oligomerization domain (NOD)-like receptors
(NLRs); RigI helicases are not currently known to be
involved in Candida recognition.
TLRs were the ﬁrst class of PRR to be described, and
have been implicated in the recognition of all major groups
of microorganisms. Shortly after their discovery, TLR2 and
TLR6 were shown to recognize the fungal cell wall prepara-
tion zymosan [13], and the TLR adaptor molecule MyD88
has been shown to be indispensable for antifungal defence
in vivo [14]. TLR2, TLR4 and TLR9 are involved in the recog-
nition of C. albicans and the induction of proinﬂammatory
cytokine production in vitro, and knockout mice deﬁcient in
TLR2 or TLR4 have altered susceptibility to disseminated
candidiasis (for review, see [9]). In contrast, TLR1 and TLR6
play redundant roles in host defence against C. albicans [15].
CLRs were the second major class of PRRs found to be
involved in the recognition of fungi in general, and C. albicans
in particular. CLRs recognize polysaccharide structures, and
because the Candida cell wall is composed of almost 90%
polysaccharides, CLRs probably constitute one of the most
important pathways for recognition of the fungus. C. albicans
is recognized by several CLRs, among which the most impor-
tant are dectin-1 (recognizing b-glucans), dectin-2, the mac-
rophage mannose receptor, the dendritic cell (DC)-speciﬁc
intercellular adhesion molecule 3-grabbing non-integrin, and
macrophage-inducible C-type lectin (Mincle) (all of these four
CLRs recognize Candida mannans), as well as the circulating
PRR mannose-binding lectin [16–21]. Other CLRs, such as
the CD36/Scarf scavenger receptors and galectin-3, are
involved in the recognition of C. albicans b-mannosides, in
close collaboration with TLR2, especially at the level of the
intestinal mucosa [22].
In addition to the cell membrane-associated classes of
PRR such as TLRs and CLRs, mammalian host defence has
evolved a second line of recognition receptor located intra-
cellularly: the RigI helicases, which are mainly receptors for
viruses, and NLRs. NLRs are known for their role in the rec-
ognition of bacterial peptidoglycans (by NOD1 and NOD2),
and also for their activation of the protein complex called
the inﬂammasome. Upon recognition of a microbial patho-
gen-associated molecular pattern or an endogenous danger
signal (e.g. uric acid or ATP), the self-assembly of the inﬂam-
masome induces activation of caspase-1, the enzyme respon-
sible for the processing of pro-interleukin (IL)-1b and pro-IL-
18 into bioactive cytokines. Whereas NOD1 and NOD2 are
not involved in the recognition of C. albicans [23], the NLRP3
inﬂammasome has been reported to have an important role
in the activation of host defence mechanisms against C. albi-
cans, especially through induction of T-helper (Th)1 and
Th17 responses, which are important for host defence
against disseminated candidiasis [24].
Thus, PRRs such as TLRs, CLRs and NLRs are the ﬁrst
components of the host defence to be engaged by the invad-
ing fungus, and their activation leads to stimulation of the
cells of the innate host defence in the ﬁrst line, and also to
the modulation of adaptive cellular responses later on during
infection.
Cell populations involved in host defence against systemic
candidiasis
Phagocytes are believed to be the most effective cells for
controlling and clearing Candida infection, with polymorpho-
nuclear neutrophils (PMNs) playing a critical role in host
defence against disseminated candidiasis [25]. Several proin-
ﬂammatory cytokines, such as IL-6 [26,27], tumour necrosis
factor (TNF) [28], and IL-17 [29,30], have been shown to
stimulate granulopoiesis and recruitment of neutrophils to
the site of infection. In addition to proinﬂammatory cyto-
kines, the haematopoietic growth factors granulocyte colony-
stimulating factor (G-CSF) and granulocyte–macrophagy
colony-stimulating factor (GM-CSF) are also critical for PMN
recruitment and activation [31,32]. In addition to direct
killing of C. albicans, PMNs are the only cells in the blood
that inhibit C. albicans germ-tube formation [33].
In addition to PMNs, mononuclear phagocytes are also
involved in host defence against disseminated candidiasis. Tis-
sue macrophages are the ﬁrst cells to encounter the patho-
genic microorganisms upon invasion, leading to production
of the chemokines and proinﬂammatory cytokines that are
central in the recruitment and activation of granulocytes and
inﬂammatory monocytes from the circulation. In a mouse
model of macrophage depletion, slower clearance of Candida
from the bloodstream was observed [34], demonstrating the
involvement of macrophages in host defence against systemic
Candida infections. In contrast, one study using depletion of
monocytes has suggested that mice with monocytopenia are
as susceptible to Candida as control mice, reinforcing the
dominant role played by PMNs in terms of host defence
against Candida infection [35].
In addition to activation of innate immune mechanisms, an
important arm of host defence is represented by cellular
adaptive immunity. As professional antigen-presenting cells,
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DCs reside and patrol the tissues, and they ingest Candida
once invasion has taken place. Candida is internalized by DCs
mainly through CLRs such as DC-speciﬁc intercellular adhe-
sion molecule 3-grabbing non-integrin and macrophage man-
nose receptor [36,37], leading to the processing and
presentation of Candida-speciﬁc antigens via major histocom-
patibility complex class II, and, upon secretion of an appro-
priate cytokine milieu, they prime Th1 and Th17 responses.
Thus, DCs bridge the innate and adaptive antifungal response
by recognizing, ingesting and processing Candida antigens.
Humoral components of anti-Candida host defence
In addition to cell-mediated responses, several blood-soluble
factors, such as complement system and antibodies, contrib-
ute to host anti-Candida immunity. All three pathways of
complement activation (the classical pathway, the alternative
pathway, and the lectin pathway) can be activated by Candida
[38,39]. The complement-opsonized or antibody-opsonized
Candida can be more efﬁciently phagocytosed [38,39],
whereas the thick fungal cell wall defends the fungus against
the killing mechanisms mediated by the membrane attack
complex of the complement system. In addition to the role
of mediating phagocytosis, complement is important for anti-
fungal defence through augmenting C. albicans-induced IL-6
and IL-1b production by the anaphylatoxin C5a (S. C. Cheng
et al., unpublished data).
In conclusion, host defence against systemic Candida infec-
tions is mediated through a combination of cellular and
humoral immune mechanisms that act in concert to recog-
nize and eliminate the invading pathogen (Fig. 1). Among
these mechanisms, however, the recruitment and activation
of PMNs by chemokines and proinﬂammatory cytokines play
a central role in antifungal immunity.
Recombinant Cytokines as Adjunctive
Therapy in Systemic Candida Infections
Although Th1 and Th17 responses are important, neutroph-
ils play the primary role in host defence against invasive or
disseminated candidiasis, and it is generally accepted that
PMNs should be central in any strategy to enhance host
defence against candidaemia and acute disseminated or inva-
sive disease. Proinﬂammatory cytokines and colony-stimulat-
ing factors are the main classes of biological actors that are
able to enforce host defence and may therefore be useful for
immunomodulation during infections. One question that has
been extensively discussed in the literature during the last
FIG. 1. Host defence against systemic Candida infections is mediated through a combination of cellular and humoral immune mechanisms that
act in concert to recognize and eliminate the invading pathogen. The ﬁrst cells to encounter the invading C. albicans are the tissue macrophages.
They release chemokines and proinﬂammatory cytokines that lead to recruitment and activation of blood neutrophils and inﬂammatory mono-
cytes, which, in turn, phagocytose and kill the fungus. Later, adaptive immune mechanisms such as Th1 and Th17 cellular responses, or humoral
antibody formation, are also induced. IFN, interferon; IL, interleukin; Mf, macrophage; NK, natural killer cell; NO, nitric oxide; PMN, polymor-
phonuclear neutrophil; Th, T-helper lymphocyte; TNF, tumour necrosis factor.
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two decades is that of the role of proinﬂammatory cytokines
during sepsis. Whereas proinﬂammatory cytokines are over-
whelmingly released during hyperacute sepsis, such as menin-
gococcal sepsis, the concentrations found during systemic
candidiasis are much lower [40]. It has therefore been pro-
posed that late-stage immunoparalysis, rather than the acute
cytokine storm, is the main immunological disturbance in sys-
temic candidiasis, and that the patient would beneﬁt from
enhancement of the host defence [31] (Fig. 2).
Colony-stimulating factors
Colony-stimulating factors were among the ﬁrst bioactive
molecules to be proposed as antifungal adjunctive therapy.
GM-CSF stimulates the haematopoiesis of myeloid cells
such as monocytes and neutrophils [41]. In addition, GM-
CSF enhances phagocytosis and the release of reactive oxy-
gen species by PMNs [42], and prolongs the survival of
neutrophils by inhibition of programmed cell death [43].
Several important antifungal mechanisms are also stimulated
by GM-CSF, such as upregulation of dectin-1 expression on
macrophages [44] and upregulation of chitotriosidase, which
cleaves the chitin from the inner cell wall of C. albicans
[45]. In neutropenic mice with disseminated candidiasis,
GM-CSF was shown to reduce lung damage and mortality
[46].
In addition to these experimental studies, initial proof-of-
concept studies in patients have also shown promising
results, although most of the studies involved severe mucosal
candidiasis patients, rather than disseminated disease. Vaz-
quez et al. investigated the use of GM-CSF as adjunctive
immunotherapy in AIDS patients with refractory mucosal
candidiasis, and its use in combination with antifungal therapy
led to clinical and mycological improvement without adverse
events [47,48]. Anecdotal reports in the literature of patients
with disseminated candidiasis showed a favourable response
when GM-CSF was added to standard antimycotic therapy
[49,50], and a patient with a 17-year history of severe
chronic mucocutaneous candidiasis showed a clinically posi-
tive response when treated with GM-CSF [51]. Although
these studies indicate that GM-CSF could be beneﬁcial in the
treatment of Candida infections, experience is limited and
controlled trials are lacking.
G-CSF is a colony-stimulating factor that selectively pro-
motes the proliferation and differentiation of neutrophils.
G-CSF enhanced the antifungal activity of PMNs [52], and,
when administered to humans, also signiﬁcantly enhanced
PMN-mediated damage of Candida pseudohyphae [53].
Furthermore, mice with disseminated candidiasis treated with
recombinant G-CSF show signiﬁcantly reduced mortality and
lower fungal outgrowth [54,55]. In a ﬁrst randomized
placebo-controlled trial addressing adjunctive immunotherapy
in non-neutropenic patients with disseminated candidiasis,
administration of G-CSF in combination with ﬂuconazole was
safe and showed a trend towards faster resolution of infec-
tion as compared with patients treated with ﬂuconazole
alone (B. J. Kullberg et al., in preparation).
FIG. 2. The role of proinﬂammatory cytokines during sepsis: whereas proinﬂammatory cytokines are overwhelmingly released during acute
meningococcal sepsis, the concentrations found during systemic candidiasis are much lower. This is partly because of differences in microbial load
in the two infections. It is therefore late-stage immunoparalysis, rather than the acute cytokine storm, that is the main immunological disturbance
in systemic candidiasis, and the patient would beneﬁt from enhancement of the host defence. LPS, lipopolysaccharide; Mo/Mf, monocyte/macro-
phage; rGM-CSF, recombinant granulocyte–macrophage colony-stimulating factor; rIFN-c, recombinant interferon-c; SIRS, systemic inﬂammatory
response syndrome; Th, T-helper lymphocyte.
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Proinﬂammatory cytokines
Several of the major proinﬂammatory cytokines, such as
TNF, IL-1, and interferon-c (IFN-c), have been shown to be
involved in the activation of antifungal host defence, and their
absence leads to increased susceptibility to systemic candidia-
sis in experimental models (for review, see [9,10]). However,
administration of recombinant TNF or IL-1 is not feasible,
owing to their strong systemic effects, which may lead to
sepsis-like symptoms. In contrast, immunotherapeutic treat-
ment with IFN-c has been available for more than two dec-
ades.
IFN-c is produced by T-cells and natural killer cells, and
augments the cytotoxic and antimicrobial properties of neu-
trophils and macrophages [56]. Various studies have shown
that IFN-c enhances the anti-Candida function of macrophag-
es [57–62], and PMNs from IFN-c-treated mice showed
enhanced killing of Candida [63]. Incubation of human PMNs
with IFN-c augments the capacity of PMNs to kill Candida
[64], and adjuvant immunotherapy with IFN-c reduces the
fungal burden in mice with disseminated candidiasis [63].
Clinical experience with IFN-c therapy is greatest in
patients with chronic granulomatous disease. In patients with
this disease, IFN-c reduces the incidence of infections, includ-
ing fungal infections with Aspergillus [65]. In addition, a small
study of three patients with disseminated candidiasis
reported that additional IFN-c therapy was beneﬁcial [50],
and a recent case series of patients with systemic fungal
infections demonstrated beneﬁcial effects of adjuvant treat-
ment with IFN-c [66]. Furthermore, administration of IFN-c
to a human immunodeﬁciency virus-infected patient with
azole-resistent oropharyngeal candidiasis resulted in a dra-
matic improvement [67]. These small studies and case
reports suggest that IFN-c could be beneﬁcial as adjuvant
antifungal therapy, but clinical trials are urgently needed to
establish whether IFN-c is valuable in the treatment of Can-
dida infections.
One of the most promising clinical conditions for the addi-
tion of adjuvant immunotherapy with IFN-c is cryptococcal
meningitis. IFN-c concentrations in the synovial ﬂuid corre-
lated with a better prognosis [68], and a clinical trial with
adjunctive recombinant IFN-c in human immunodeﬁciency
virus patients with cryptococcal meningitis showed a trend for
a better prognosis as compared with standard antimycotic
therapy alone [69]. The results of a second trial, which has
been recently completed in South Africa, are eagerly awaited.
Adoptive transfer of primed immune cells
A more sophisticated approach to antifungal immunotherapy
could be the adoptive transfer of antigen-primed DCs, which
would skew the adaptive immunity towards anti-Candida
Th1/Th17 responses [70]. DCs can be primed ex vivo to
induce speciﬁc cytokine proﬁles, and thereafter infused into
the patient with Candida infection [71]. This approach has
been attempted in experimental models of candidiasis, in
which Th1 antifungal responses could be induced by adoptive
transfer of DCs (DC vaccination) in mice that received allo-
geneic bone marrow transplants [72].
In addition to DC vaccination, adoptive transfer of anti-
Candida T-cells has been proposed as potential immunother-
apy in patients with Candida infection after haematopoietic
stem cell transplantation [73]. As the generated T-cells do
not seem to be affected by cryopreservation [73], this pre-
sents an opportunity to generate autologous anti-Candida T-
cells before the patients reach an immunocompromised sta-
tus, and adoptively transfer these cells if needed when the
patient develops candidiasis. However, the efﬁcacy and
potential adverse effects of this approach still have to be
assessed in experimental Candida infection models before it
can be attempted in patients.
Concluding Remarks
Systemic Candida infections are still accompanied by an unac-
ceptably high burden of morbidity and mortality, despite the
introduction in the last decade of novel and more potent an-
timycotic drugs. New therapeutic approaches are therefore
needed to improve the outcome of the diseases, and one
obvious solution would be the use of adjuvant immunother-
apy, with the aim of improving host defence against Candida.
The increase in our understanding of the mechanisms that
underlie the pathogenesis of Candida infections is bringing
the development of efﬁcient and feasible immunotherapeutic
strategies closer to clinical practice. In the present review,
we give an update, of both experimental data and proof-of-
principle studies in humans, that argues for the use of
adjunctive immunotherapy with recombinant cytokines in
invasive candidiasis. Sufﬁciently powered studies on the role
of cytokine-based treatment regimens for invasive candidiasis
are needed to fully demonstrate the feasibility of the immu-
notherapy approach to improve the prognosis of severe inva-
sive Candida infections.
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